EGFR and non-small cell lung carcinoma: For example, one study found that NSCLC patients who developed resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs) but did not have a secondary T790M mutation might benefit from ICI monotherapy due to an increase in PD-L1 expression and tumor mutation burden (10).